Freienbach, Switzerland, January 13, 2015 – EffRx Pharmaceuticals SA, a specialty pharmaceutical company focused on the development of novel therapeutic entities for a variety of orphan and specialty indications, today announced the signing of an agreement with Andrus Ltd. to develop products for commercialization in Russia and CIS countries. “We are excited to further expand […]
New Partnerships Significantly Expand Global Footprint for Proprietary Buffered Effervescent Osteoporosis Therapy Freienbach, Switzerland — EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced the signing of two new distribution agreements that will bring its osteoporosis treatment, Binosto®, to strategic markets in Russia, CIS countries and Africa. “We are excited to expand the global footprint
EffRx Signs Binosto® Distribution Agreements in Russia and Africa Read More »
New Partnerships Significantly Expand Global Footprint for Proprietary Buffered Effervescent Osteoporosis Therapy Freienbach, Switzerland — EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced the signing of two new distribution agreements that will bring its osteoporosis treatment, Binosto®, to strategic markets in Russia, CIS countries and Africa. “We are excited to expand the global footprint
EffRx Signs Binosto® Distribution Agreements in Russia and Africa Read More »
Freienbach, February 4th 2014 – EffRx Pharmaceuticals S.A. today announced that it has signed exclusive distribution agreements with three leading local pharmaceutical companies in Italy, Spain and Portugal for Binosto® – EffRx’s innovative osteoporosis medication. Under the terms of the agreement, EffRx grants exclusive marketing authorization and distribution rights to Abiogen Pharma SpA. for Italy, Lacer S.A. for
EffRx signs distribution agreements for Binosto® in Italy, Spain and Portugal Read More »
Freienbach, 03 June 2013 – EffRx Pharmaceuticals S.A. today announces the signing of an exclusive distribution agreement with Ahn-Gook Pharmaceutical Co. Ltd for Binosto – EffRx’s innovative osteoporosis medication – for the Korean market. Under the terms of the agreement, EffRx grants exclusive rights to Ahn-Gook to register, market and distribute Binosto® in South Korea.
EffRx signs distribution agreement with Ahn-Gook Pharma for Binosto® for Korea Read More »
EffRx signs a distribution agreement with Hikma Pharmaceuticals for Binosto® in MENA Freienbach, 4 February 2013 – EffRx Pharmaceuticals SA today announces the signing of a distribution agreement with Hikma Pharmaceuticals for Binosto®, EffRx’s innovative osteoporosis medication, for the Middle East and North Africa (“MENA”) region. Binosto® is the first and only buffered solution for
Agreement with Hikma Pharmaceuticals Read More »
